Advertisement
Merck
Subscribe to Merck

The Lead

FDA OKs Gardasil 9 to Prevent Cancers Caused by Five Additional Types of HPV

December 10, 2014 3:27 pm | News | Comments

The FDA has approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than Gardasil, Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.

Merck Advances Breast Cancer Drug

December 10, 2014 1:44 pm | by The Associated Press | News | Comments

Merck will advance a new cancer drug into bigger patient tests, after promising findings in an...

Cubist Patent Losses Won't Deter Merck

December 9, 2014 10:03 am | by The Associated Press | News | Comments

Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a...

Sigma-Aldrich Stockholders Approve Acquisition by Merck KGaA

December 8, 2014 8:50 am | News | Comments

Sigma-Aldrich Corporation stockholders voted to adopt the previously announced merger agreement...

View Sample

FREE Email Newsletter

Merck Buys Cubist Pharmaceuticals for $8.4B

December 8, 2014 7:53 am | News | Comments

Merck is buying Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called "superbugs" that are drawing dire warnings from global health organizations.           

Merck and NewLink Genetics to Collaborate on Investigational Ebola Vaccine

November 24, 2014 8:26 am | News | Comments

Merck and NewLink Genetics Corporation have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.       

Study Lifts Cloud Over Heart Drugs Zetia, Vytorin

November 18, 2014 8:31 am | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.

Advertisement

Merck and Pfizer to Develop Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

November 17, 2014 8:15 am | News | Comments

Merck announced today that it has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

Gene Study Boosts Interest in Heart Drug Zetia

November 12, 2014 5:09 pm | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

Scientists have discovered some rare gene mutations that give people naturally lower cholesterol levels and cut their risk of heart disease in half. The news is of great interest because a drug that mimics these mutations has long been sold without evidence that it cuts the chance of heart disease, even though it lowers cholesterol.

Merck's Third Quarter Net Income Falls But Profits Top Analysts' Estimates

October 27, 2014 8:31 am | News | Comments

Merck's third-quarter net income fell mostly because of large costs tied to acquisitions and divestitures. But the company's adjusted earnings topped Wall Street's view, and it narrowed its full-year adjusted earnings forecast on Monday.  

Merck Ex-Financial Analyst Facing Insider Trading Charge

October 15, 2014 8:14 am | News | Comments

A former senior finance analyst at Merck & Co. is facing an insider trading charge after authorities said Tuesday that he passed secrets to a friend he met at college that earned $722,000 in illegal profits.       

Merck Completes Sale of Consumer Unit to Bayer

October 1, 2014 3:15 pm | News | Comments

Merck has completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion.        

Advertisement

Merck KGaA to Buy Sigma Aldrich for $17B

September 22, 2014 7:44 am | by David Mchugh - AP Business Writer - Associated Press | News | Comments

Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion. Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich's shares — a premium of 37 percent over Friday's closing price of $102.37.

Merck KGaA Strengthens Executive Board

September 18, 2014 2:20 pm | News | Comments

Merck KGaA today announced that the Board of Partners has promoted Stefan Oschmann to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belén Garijo was appointed to the Executive Board to take over leadership for the Pharma business.

Sun Pharma and Merck Announce $80M Licensing Agreement for Tildrakizumab

September 17, 2014 9:00 am | News | Comments

Merck and Sun Pharmaceutical Industries have announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis.

Merck KGaA Discontinues Clinical Development Program of Tecemotide for Stage III Non-Small Cell Lung Cancer

September 12, 2014 3:18 pm | News | Comments

Merck KGaA announced that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).

Shortage of Bladder Cancer Drug Could be Tragic for Patients, Doctor Says

September 9, 2014 8:32 am | by Sheryl Ubelacker, The Canadian Press | News | Comments

The shortage of the medication — called bacillus Calmette-Guerin, or BCG — has been caused by manufacturing problems at plants operated by two different pharmaceutical companies — Merck and Sanofi Pasteur.        

Advertisement

FDA Approves Keytruda for Advanced Melanoma

September 4, 2014 3:49 pm | News | Comments

The U.S. Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.       

Pfizer And Merck to Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen

August 26, 2014 8:35 am | News | Comments

Pfizer and Merck announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer.

FDA Approves New Sleeping Drug from Merck

August 13, 2014 4:29 pm | by The Associated Press | News | Comments

Merck & Co. has won federal approval for a new type of sleeping pill designed to help people with insomnia stay asleep. The tablet, Belsomra, works by temporarily blocking chemicals known as orexins that control the sleep cycle and can keep people awake at night.

Merck Second Quarter Profit More Than Doubles

July 29, 2014 7:29 am | by The Associated Press | News | Comments

Merck has reported earnings that more than doubled in its second quarter, and topped analysts' expectations. The Whitehouse Station, New Jersey-based company said net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.

Merck Initiates Phase III Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus Infection in High-Risk Bone Marrow Transplant Patients

July 24, 2014 8:51 am | News | Comments

The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants.

Studies See New Risks for Cholesterol Drug Niacin

July 16, 2014 6:31 pm | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use.  

Merck KGaA’s Biopharmaceutical Division Appoints New Global Head of R&D

July 14, 2014 9:13 am | News | Comments

Merck KGaA’s biopharmaceutical division today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.          

Bionomics and Merck Enter New Alzheimer's Research Collaboration

June 24, 2014 8:16 am | News | Comments

Bionomics Limited has entered into an exclusive Research Collaboration and License Agreement with Merck, known as MSD outside the United States and Canada, for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions.

Merck Starting Tender Offer for Idenix

June 20, 2014 9:35 am | by The Associated Press | News | Comments

Merck announced earlier this month that it would pay about $3.85 billion for the Cambridge, Massachusetts-based company. Merck is hoping that teaming Idenix's hepatitis C medicines with its experimental drugs will produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.

Merck to Acquire Idenix

June 9, 2014 8:04 am | News | Comments

Merck and Idenix Pharmaceuticals today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.85 billion, has been approved by the boards of directors of both companies.

$100M NuvaRing Settlement Finalized

June 5, 2014 3:33 pm | by JIM SALTER, Associated Press | News | Comments

A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that the vast majority of claimants have chosen to opt into the agreement, those involved in the lawsuits said Thursday.

New Allergy Tablets Offer Alternative to Shots

June 2, 2014 6:51 am | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

For decades, seasonal allergy sufferers had two therapy options to ease the misery of hay fever. They could swallow pills or squirt nasal sprays every day for brief reprieves from the sneezing and itchy eyes. Or they could get allergy shots for years to gradually reduce their immune system's...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading